Myriad Teams with Topin to Market OnDose to Oncologists | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics has chosen Topin & Associates to help with its marketing strategy for a molecular diagnostic test to determine proper dosing for cancer drug 5-fluorouracil.

Under the terms of the deal, Topin will create a marketing strategy around the test, called OnDose, and prepare material in order to aid Myriad's sales force in selling the test to oncologists.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: transcriptomic analysis of the Venus flytrap, SMASH approach for CNV analysis, and more.

A Caltech professor wins the Millennium Technology Prize that lauds technological advances that improve human life.

San Diego's biotech scene has a dearth of executives who are women, Stat News reports.

Some 90 percent of respondents to a Nature survey say there is a research reproducibility crisis.